12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens

Background. Highly effective hepatitis C virus (HCV) direct-acting antiviral therapies that do not require modification of human immunodeficiency virus (HIV) antiretroviral regimens are needed. We evaluated the efficacy and safety of daclatasvir + sofosbuvir (DCV + SOF) for 12 weeks by antiretrovira...

Descripción completa

Detalles Bibliográficos
Autores principales: Luetkemeyer, Anne F., McDonald, Cheryl, Ramgopal, Moti, Noviello, Stephanie, Bhore, Rafia, Ackerman, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885650/
https://www.ncbi.nlm.nih.gov/pubmed/27025835
http://dx.doi.org/10.1093/cid/ciw163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885650/
https://www.ncbi.nlm.nih.gov/pubmed/27025835
http://dx.doi.org/10.1093/cid/ciw163

Ejemplares similares